查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983915

生物製造關鍵蛋白市場：按產品類型、原料、應用、最終用途和分銷管道分類的全球市場預測－2026-2030年

Vital Proteins for Biomanufacturing Market by Product Type, Source, Application, End-Use, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年生物製造關鍵蛋白質市場價值為 565.2 億美元，預計到 2025 年將成長至 614.7 億美元，年複合成長率為 9.00%，到 2030 年將達到 948.1 億美元。

主要市場統計數據
基準年 2024 565.2億美元
預計年份：2025年 614.7億美元
預測年份 2030 948.1億美元
複合年成長率 (%) 9.00%

權威概述了膠原蛋白、明膠和水解物如何幫助現代生物製造工作流程並推動跨學科創新。

關鍵蛋白質是生物製造的基礎材料，為生命科學和商業領域的廣泛應用提供必要的結構、功能和生物活性。在生物製造中，膠原蛋白、明膠和膠原蛋白水解物具有至關重要的性能特徵。膠原蛋白支持組織支架的建構和機械完整性，明膠可用於成型、包覆和控釋，而水解物則提供適用於製劑和細胞訊號傳導的水溶性生物活性胜肽。這三類材料構成了一個材料複雜性的連續光譜，為組織工程、藥物遞送、再生醫學和功能性營養等領域的創新提供了支持。

生物技術原料採購、永續性措施和先進加工技術如何融合，從而改變關鍵蛋白質應用中的供應鏈和材料性能？

在生物製造的關鍵蛋白質領域，正在發生多項變革性變化，這些變化正在重新定義上游採購和下游應用。首先，生物技術主導的採購正在加速重組蛋白和工程化表現平台的應用。這些技術減少了對傳統動物性原料的依賴，提高了批次間的一致性，並實現了對功能域的序列級控制。這種轉變支持了醫療和製藥領域的應用，這些領域對可追溯性和降低免疫抗原性風險的要求很高。其次，出於對永續性的關注，製造商正在尋求低碳且符合倫理的替代方案，尤其重視海洋資源和產品特定的價值提升策略。這些趨勢與供應鏈多元化和新型認證系統的建立密切相關。

評估近期針對蛋白質原料的關稅措施如何影響供應鏈，並改變籌資策略、庫存管理和創新重點。

近期影響蛋白質原料和中間投入品的貿易政策措施對採購、生產和購買決策產生了連鎖反應。對某些動物性和加工蛋白進口產品的關稅調整增加了依賴跨境原料流動的製造商的接收成本，促使他們迅速審查供應商組合和合約條款。因此，一些公司優先考慮近岸外包、長期固定價格合約或投資國內加工能力，以降低價格波動並維持受監管終端用途的生產連續性。

全面的細分分析表明，產品類型、原料變化、應用需求、最終用途要求和分銷模式如何共同影響策略和規格決策。

一套精細的細分框架揭示了每種產品類型、原料、應用、最終用途和分銷管道的不同需求、風險特徵和商業策略。膠原蛋白、明膠和水解物等產品類型的差異，對應不同的技術規格和加工需求。在膠原蛋白中，I型、II型和III型的功能作用分別需要不同的分析控制和針對特定應用的關注點；而A型和B型明膠則影響凝膠特性和配方行為。水解物根據其高低分子量分佈進行區分，在生物活性和溶解度方面表現出不同的性能特徵，這些特徵直接指南醫療和營養應用領域的配方決策。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和需求模式決定了採購、監管和商業化的優先事項。

區域趨勢持續影響關鍵蛋白質全球價值鏈的策略重點和競爭定位。在美洲，成熟的畜牧業和發達的水產養殖業為牛和豬源性原料的穩定供應提供了保障，而不斷成長的營養保健品和機能性食品市場則推動了對高純度水解物和膠原蛋白衍生物的需求，尤其是在消費者配方方面。該地區的監管執法和自願性可追溯性計劃提高了人們對產品品質的期望，許多製造商正在投資建立透明的供應鏈和認證體系，以促進跨境貿易和臨床應用。

深入了解老牌製造商、特殊​​原料製造商和新興生物技術參與企業如何透過合併、差異化和策略聯盟來競爭。

關鍵蛋白質領域的競爭格局呈現出複雜多樣的態勢，既有老牌生產商，也有特種原料供應商，還有利用生技的新興參與企業。老牌供應商持續投資於製程管制、認證和規模化生產，以滿足動物營養和大眾市場個人照護等大量生產需求。同時，特種原料供應商則透過高純度醫用級產品、先進的分餾技術以及針對特定營養補充劑和藥品應用的客製化胜肽開發來脫穎而出。生技領域的新興參與企業則透過引入重組表達平台和精準設計的序列，重塑了競爭格局，挑戰了傳統的採購模式。

為領導企業提供切實可行的策略行動，以降低供應風險、提高材料性能，並透過夥伴關係和有針對性的研發抓住高附加價值機會。

產業領導企業應優先採取一系列切實可行的措施，以應對供應波動、日益複雜的監管環境以及對先進蛋白質材料不斷變化的需求。首先，投資於多元化的籌資策略，將傳統來源與海洋來源、重組來源和產品特定來源結合，以降低單一來源供應中斷的風險，並回應不斷變化的客戶偏好。其次，加快製程改善和分析能力的提升，從而嚴格控制分子量分佈、交聯度和純度，提供滿足醫療保健和製藥客戶嚴苛要求的材料。第三，透過第三方認證、生產歷史（監管鏈）文件和生命週期評估，永續性市場。

實證調查方法：結合專家訪談、技術文獻分析、供應鏈映射和情境評估，得出可操作的見解。

本分析的調查方法整合了多種證據來源，旨在為關鍵蛋白質領域提供嚴謹且切實可行的觀點。主要定性資料透過與製造商、材料科學家、配方專家、法規顧問和通路合作夥伴進行結構化訪談所獲得，以了解實際營運、技術限制和商業策略。次要研究涵蓋同行評審的科學文獻、專利申請、標準文件和法規指南，以檢驗技術聲明並闡明醫療保健、製藥和消費品應用領域的監管環境。

一項權威的綜合分析突顯了策略重點，將供應鏈韌性、材料工程和監管合規性轉化為競爭優勢。

總之，生物技術的發展、對永續性的需求以及市場的成熟，共同提升了膠原蛋白、明膠和水解物在生物製造領域的戰略重要性。這些材料不再只是普通的原料，而是經過工程改造的組分，其在醫療、製藥和先進營養等領域的高價值應用適用性取決於其分子特性、來源和監管狀態。隨著價值鏈適應不斷變化的貿易政策，以及新的生產方法日益普及，那些兼具卓越技術、多元化採購管道和清晰品質保證體系的企業將獲得顯著優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製造的關鍵蛋白質市場：依產品類型分類

  • 親和性和配體和結合蛋白質
    • 蛋白質A
    • 蛋白質G
    • 蛋白質L
    • 鏈黴親和素/親和素
  • 載體蛋白
    • 白蛋白
    • 鐵蛋白和其他
    • 轉鐵蛋白
  • Chaperone和摺疊輔助因子
    • 分子伴侶
    • 蛋白質二硫鍵異構酶
  • 酵素
    • 糖苷酶
    • 激酶
    • 紗布
    • 核酸酶
    • 聚合酵素
    • 蛋白酶
  • 細胞外基質和包被
    • 膠原蛋白
    • 纖連蛋白
    • 層黏連蛋白
    • 玻璃粘連蛋白
  • 生長因子和細胞激素
    • EGF家族
    • FGF家族
    • IGF/胰島素家族
    • 白細胞介素和趨化素
    • TGF-BETA/BMP家族
    • VEGF/PDGF家族
  • 血清替代
    • 預先定義的蛋白質混合物
    • 重組白蛋白混合物

第9章 生物製造的關鍵蛋白質市場：依來源分類

  • 動物源性
  • 無細胞系統
  • 哺乳動物細胞系統
  • 微生物表現系統
  • 植物來源
  • 重組

第10章：生物製造的關鍵蛋白質市場：按應用領域分類

  • 動物飼料
    • 水產飼料
    • 牲畜飼料
    • 寵物食品
  • 化妝品
    • 護髮
    • 口腔護理
    • 護膚
  • 醫療設備
    • 鷹架材料
    • 外科植入
    • 傷口敷料
  • 營養保健品
    • 骨骼健康
    • 關節健康
    • 皮膚健康
    • 運動營養
  • 製藥
    • 藥物輸送
    • 組織工程
    • 創傷治療

第11章 生物製造的關鍵蛋白質市場：依最終用途分類

  • 學術和研究機構
  • 合約研究組織（CRO）
  • 製藥和生物技術公司

第12章：生物製造的關鍵蛋白質市場：依分銷管道分類

  • 直銷
  • 銷售代理

第13章：生物製造的關鍵蛋白質市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生物製造的關鍵蛋白質市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 生物製造的關鍵蛋白質市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物製造關鍵蛋白質市場

第17章：中國生物製造關鍵蛋白市場

第18章 競爭格局

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • Danaher Corporation
  • Darling Ingredients Inc.
  • Gelita AG
  • Humabiologics, Inc
  • Lonza Group AG
  • Merck KGaA
  • Nitta Gelatin, Inc.
  • Thermo Fisher Scientific Inc.
  • Weishardt International
Product Code: MRR-D47730F51F28

The Vital Proteins for Biomanufacturing Market was valued at USD 56.52 billion in 2024 and is projected to grow to USD 61.47 billion in 2025, with a CAGR of 9.00%, reaching USD 94.81 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 56.52 billion
Estimated Year [2025] USD 61.47 billion
Forecast Year [2030] USD 94.81 billion
CAGR (%) 9.00%

An authoritative overview of how collagen, gelatin, and hydrolysates enable modern biomanufacturing workflows and drive crossdisciplinary innovation

Vital proteins function as foundational materials in biomanufacturing, supplying structural, functional, and bioactive properties essential to a broad array of life science and commercial applications. Within biomanufacturing, collagen, gelatin, and collagen-derived hydrolysates provide key performance attributes: collagen supports tissue scaffolding and mechanical integrity; gelatin enables molding, encapsulation, and controlled release; and hydrolysates offer soluble bioactive peptides suited to formulation and cellular signaling. Together, these classes form a continuum of material complexity that underpins innovations in tissue engineering, drug delivery, regenerative medicine, and functional nutrition.

As industry actors increasingly integrate biotechnology and materials science, the role of these proteins has expanded from commodity ingredients to engineered biomaterials. This transition has been driven by advances in recombinant expression systems, process-scale purification, and tailored molecular modification. Consequently, researchers and manufacturers now demand consistent molecular profiles, traceable raw materials, and regulatory-compliant production pathways. The introduction of recombinant and nontraditional sources is reshaping supply strategies, while downstream processing improvements are enabling higher-purity grades and performance-tuned variants that meet the rigorous needs of clinical and high-value commercial uses.

Given these dynamics, stakeholders must reconcile material performance with sourcing risk, regulatory trajectory, and commercialization timelines. Effective decision-making requires integrated visibility into product differentiation across collagen types and gelatin classes, the implications of molecular weight distributions in hydrolysates, and the alignment of material specifications with application-level requirements in medical devices, pharmaceuticals, and advanced nutrition.

How biotechnology sourcing, sustainability commitments, and advanced processing are converging to transform supply chains and material performance in vital protein applications

The landscape for vital proteins in biomanufacturing is undergoing several transformative shifts that are redefining both upstream sourcing and downstream application. First, biotechnology-driven sourcing is accelerating adoption of recombinant proteins and engineered expression platforms that reduce reliance on traditional animal sources while improving batch-to-batch consistency and enabling sequence-level control of functional domains. This shift, in turn, supports medical and pharmaceutical use-cases that demand traceability and reduced immunogenic risk. Second, sustainability considerations are elevating marine and byproduct valorization strategies as manufacturers seek lower-carbon, ethically aligned alternatives; these trends interact with supply chain diversification initiatives and new certification schemes.

Concurrently, advances in material science and processing are expanding the functional envelope of these proteins. Precision hydrolysis and fractionation techniques allow producers to tailor molecular weight distributions and peptide profiles to optimize bioactivity, solubility, and rheology for specific applications. In parallel, integrated manufacturing models are bringing bioprocessing, formulation, and device assembly closer together, facilitating co-development of materials and products and shortening innovation cycles. Regulatory evolution also plays a formative role: clearer pathways for medical-grade materials and harmonized quality standards are enabling faster adoption in implantable devices and tissue-engineering constructs. Altogether, these shifts are fostering an ecosystem where material innovation, ethical sourcing, and regulatory clarity converge to unlock new commercial opportunities.

Assessment of how recent tariff measures on protein inputs have propagated through supply chains to alter sourcing strategies, inventory management, and innovation priorities

Recent trade policy measures affecting proteinaceous raw materials and intermediate inputs have produced cascading operational and strategic effects across sourcing, manufacturing, and procurement decisions. Tariff adjustments imposed on certain animal-derived and processed protein imports have elevated landed costs for manufacturers that rely on cross-border raw material flows, prompting rapid reassessment of supplier portfolios and contract terms. As a result, some firms prioritized nearshoring, long-term fixed-priced contracts, or investment in domestic processing capabilities to mitigate volatility and maintain production continuity for regulated end uses.

Beyond direct cost effects, tariff-driven shifts have impacted supplier behavior and inventory management practices. Manufacturers have responded by increasing safety stocks for critical inputs and accelerating qualification of alternative sources, including marine and recombinant supply streams, to preserve product timelines and regulatory traceability. In addition, the policy environment has intensified focus on tariff classification and valuation strategies, as well as on optimizing inbound logistics to minimize duty exposure through strategic routing and free trade agreement utilization.

Importantly, tariffs also influenced innovation choices. Facing elevated input expense, some developers reallocated R&D budgets toward process intensification, yield improvements, and higher-value product formulations that reduce raw material intensity per unit of value. Consequently, the cumulative impact of trade measures extended beyond short-term cost inflation to encourage structural changes in sourcing strategies, manufacturing investments, and product design decisions that enhance resilience and long-term competitiveness.

Comprehensive segmentation analysis showing how product types, source variants, application demands, end-use requirements, and distribution models jointly shape strategy and specification decisions

A nuanced segmentation framework reveals differentiated requirements, risk profiles, and commercial strategies across product types, sources, applications, end uses, and distribution channels. Product type distinctions among collagen, gelatin, and hydrolysates correspond to divergent technical specifications and processing needs; within collagen, the functional roles of Type I, Type II, and Type III demand separate analytical controls and application focus, while gelatin classes Type A and Type B influence gelation properties and formulation behavior. Hydrolysates differentiated by high and low molecular weight profiles command distinct performance characteristics in bioactivity and solubility, which directly inform formulation decisions for medical versus nutritional applications.

Source-based segmentation highlights tradeoffs between traditional and emerging supply streams. Bovine, marine, and porcine origins each carry unique regulatory, cultural, and safety considerations, while recombinant production offers sequence-defined materials with enhanced traceability and reduced zoonotic risk. Application segmentation ties material selection tightly to end-function: animal nutrition formulations require tailored peptide profiles for digestibility and palatability; cosmetics prioritize sensory and skin interaction properties across hair care, oral care, and skin care; medical device developers focus on scaffold mechanics, implant compatibility, and wound dressing performance; nutraceuticals and pharmaceutical developers demand rigorous bioactivity, stability, and delivery characteristics for bone, joint, skin, sports nutrition, drug delivery, and tissue-engineering uses.

End-use segmentation further refines commercial pathways, as product specifications for animal nutrition, dietary supplements, functional foods, medical applications, and personal care diverge in regulatory regimes, quality expectations, and channel economics. Distribution channel segmentation underscores how institutional sales, offline retail, and online retail impose different packaging, labeling, and supply cadence requirements, with institutional buyers such as food service and healthcare institutions seeking bulk supply agreements and stringent certification, while brand websites and e-commerce platforms emphasize direct-to-consumer traceability and shelf-ready presentation. Together, these segmentation dimensions create a matrix of technical and commercial considerations that companies must navigate to align product development, manufacturing, and go-to-market strategies.

Regional dynamics and demand patterns across the Americas, Europe Middle East Africa, and Asia Pacific that determine sourcing, regulation, and commercialization priorities

Regional dynamics continue to shape strategic priorities and competitive positioning across the global value chain for vital proteins. In the Americas, established livestock industries and developed aquaculture sectors support a steady supply of bovine and porcine raw materials, while a growing nutraceutical and functional food market drives demand for high-purity hydrolysates and collagen derivatives tailored for consumer-facing formulations. Regulatory enforcement and voluntary traceability programs in this region reinforce quality expectations, prompting many manufacturers to invest in transparent supply chains and certification schemas that facilitate cross-border trade and clinical translation.

In Europe, Middle East, and Africa, a complex mix of regulatory jurisdictions, sustainability priorities, and rising medical device activity is accelerating demand for ethically sourced and marine-derived proteins. The region's emphasis on environmental compliance and circularity fosters innovation in byproduct valorization and alternative sourcing, while harmonization efforts across regulatory authorities create clearer pathways for medical-grade materials. Meanwhile, the Asia-Pacific region remains a major production and consumption hub, underpinned by large-scale aquaculture, expanding consumer markets for beauty and health products, and rapid adoption of recombinant and marine technologies. This region's cost-efficient manufacturing base, combined with rising domestic R&D capacity, positions it as both an exporter of raw materials and an increasingly sophisticated developer of finished formulations and devices.

Taken together, these regional insights emphasize the need for diversified sourcing strategies, regulatory agility, and market-specific product positioning. Companies that align production footprints, quality systems, and commercial channels with regional demand characteristics will be better equipped to capture cross-border opportunities and respond to localized regulatory and consumer trends.

Insights into how legacy producers, specialty ingredient firms, and biotech entrants are competing through integration, differentiation, and strategic collaboration

Competitive dynamics among companies in the vital proteins space reflect a blend of legacy producers, specialty ingredient firms, and new entrants leveraging biotechnology. Established suppliers continue to invest in process control, certification, and scale to serve high-volume applications such as animal nutrition and mass-market personal care, while specialty firms differentiate through high-purity medical-grade offerings, advanced fractionation capabilities, and custom peptide development for targeted nutraceutical and pharmaceutical uses. New biotechnology entrants are reshaping the competitive set by introducing recombinant expression platforms and precision-engineered sequences that challenge conventional sourcing assumptions.

Strategic approaches vary: some companies pursue integrated value chains that combine raw material sourcing, downstream purification, and formulation services to capture margin and accelerate time to market; others adopt asset-light models, focusing on proprietary formulations, branding, and channel partnerships to scale presence in direct-to-consumer and institutional channels. Mergers, strategic partnerships, and contract manufacturing collaborations have become common mechanisms to acquire technical capabilities or expand geographic reach without committing to greenfield capacity. Across the competitive landscape, one recurring theme is the premium placed on traceability, quality systems, and regulatory alignment, especially for suppliers targeting medical devices and pharmaceutical applications. Companies that invest in robust quality management systems, transparent provenance, and technical support services position themselves as preferred partners for high-value, regulated customers, while those prioritizing cost leadership maintain competitiveness in large-volume consumer segments.

Practical strategic actions for leaders to reduce supply risk, enhance material performance, and capture highvalue opportunities through partnerships and targeted R and D

Industry leaders should prioritize a set of pragmatic actions to navigate supply volatility, regulatory complexity, and shifting demand for advanced protein materials. First, invest in diversified sourcing strategies that combine traditional sources with marine, recombinant, and byproduct-derived streams to reduce exposure to single-source disruptions and to meet evolving customer preferences. Second, accelerate adoption of process improvements and analytical capabilities that enable tight control over molecular weight distribution, crosslinking, and purity, thereby delivering materials that meet the stringent requirements of medical and pharmaceutical customers. Third, strengthen quality, traceability, and sustainability credentials through third-party certification, chain-of-custody documentation, and lifecycle assessments to differentiate offerings and facilitate market access across jurisdictions.

Additionally, prioritize strategic partnerships and flexible manufacturing agreements to scale rapidly without incurring disproportionate capital risk. Invest selectively in R&D that targets high-margin applications where materials science and bioactivity confer defensible product advantages, such as tissue-engineered scaffolds, drug-delivery matrices, and clinically validated nutraceuticals. Finally, align commercial models with channel-specific needs by offering formulation support, tailored packaging, and technical training for institutional buyers, while developing direct-to-consumer narratives that emphasize provenance, efficacy, and sustainability. Implementing these actions in a coordinated manner will enhance resilience, accelerate innovation, and maximize commercial returns across a range of end markets.

An evidence driven methodology combining expert interviews, technical literature analysis, supply chain mapping, and scenario evaluation to support actionable insights

The research methodology underpinning this analysis integrates multiple evidence streams to produce a rigorous, actionable perspective on the vital proteins landscape. Primary qualitative inputs include structured interviews with manufacturers, material scientists, formulation experts, regulatory advisers, and channel partners to capture operational realities, technical constraints, and commercial strategies. Secondary review encompassed peer-reviewed scientific literature, patent filings, standards documentation, and regulatory guidance to validate technical assertions and to map the regulatory context for medical, pharmaceutical, and consumer applications.

Analytical processes involved crosswalks between product specifications and application requirements to identify performance gaps and opportunities, coupled with supply chain mapping to reveal sourcing dependencies and logistic vulnerabilities. Scenario analysis explored plausible policy and trade developments, manufacturing scale pathways, and technology adoption curves to assess strategic implications. Throughout the methodology, emphasis was placed on triangulation of findings and on documenting source provenance to ensure confidence in conclusions. Where heterogeneity existed in respondent perspectives, the analysis highlighted areas of consensus and divergence to support informed decision-making rather than singular predictive claims.

A decisive synthesis highlighting the strategic priorities that convert supply chain resilience, material engineering, and regulatory alignment into competitive advantage

In conclusion, the confluence of biotechnology, sustainability imperatives, and market sophistication is elevating the strategic importance of collagen, gelatin, and hydrolysates within biomanufacturing. These materials are no longer solely commodity inputs; they are engineered components whose molecular characteristics, provenance, and regulatory posture determine suitability for high-value applications in medicine, pharmaceuticals, and advanced nutrition. As supply chains adjust to trade policy shifts and as new production modalities gain traction, companies that marry technical excellence with diversified sourcing and clear quality documentation will capture disproportionate value.

Moving forward, the path to competitive advantage rests on three interconnected priorities: secure and verifiable supply chains, invest in process and analytical capabilities that deliver application-specific performance, and pursue market strategies that align product attributes with regional regulatory expectations and channel requirements. By focusing resources where material differentiation creates defensible commercial advantage, organizations can turn current disruptions into catalysts for innovation and sustainable growth in next-generation biomanufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vital Proteins for Biomanufacturing Market, by Product Type

  • 8.1. Affinity Ligands & Binding Proteins
    • 8.1.1. Protein A
    • 8.1.2. Protein G
    • 8.1.3. Protein L
    • 8.1.4. Streptavidin/Avidin
  • 8.2. Carrier Proteins
    • 8.2.1. Albumins
    • 8.2.2. Ferritin & Others
    • 8.2.3. Transferrins
  • 8.3. Chaperones & Folding Aids
    • 8.3.1. Chaperonins
    • 8.3.2. Protein Disulfide Isomerase
  • 8.4. Enzymes
    • 8.4.1. Glycosidases
    • 8.4.2. Kinases
    • 8.4.3. Ligases
    • 8.4.4. Nucleases
    • 8.4.5. Polymerases
    • 8.4.6. Proteases
  • 8.5. Extracellular Matrix & Coatings
    • 8.5.1. Collagens
    • 8.5.2. Fibronectins
    • 8.5.3. Laminins
    • 8.5.4. Vitronectin
  • 8.6. Growth Factors & Cytokines
    • 8.6.1. EGF Family
    • 8.6.2. FGF Family
    • 8.6.3. IGF/Insulin Family
    • 8.6.4. Interleukins & Chemokines
    • 8.6.5. TGF-Beta/BMP Family
    • 8.6.6. VEGF/PDGF Family
  • 8.7. Serum Replacements
    • 8.7.1. Defined Protein Mixes
    • 8.7.2. Recombinant Albumin Blends

9. Vital Proteins for Biomanufacturing Market, by Source

  • 9.1. Animal-Derived
  • 9.2. Cell-Free Systems
  • 9.3. Mammalian Cell Systems
  • 9.4. Microbial Expression Systems
  • 9.5. Plant-Based
  • 9.6. Recombinant

10. Vital Proteins for Biomanufacturing Market, by Application

  • 10.1. Animal Nutrition
    • 10.1.1. Aquaculture Feed
    • 10.1.2. Livestock Feed
    • 10.1.3. Pet Food
  • 10.2. Cosmetics
    • 10.2.1. Hair Care
    • 10.2.2. Oral Care
    • 10.2.3. Skin Care
  • 10.3. Medical Devices
    • 10.3.1. Scaffold Materials
    • 10.3.2. Surgical Implants
    • 10.3.3. Wound Dressings
  • 10.4. Nutraceuticals
    • 10.4.1. Bone Health
    • 10.4.2. Joint Health
    • 10.4.3. Skin Health
    • 10.4.4. Sports Nutrition
  • 10.5. Pharmaceuticals
    • 10.5.1. Drug Delivery
    • 10.5.2. Tissue Engineering
    • 10.5.3. Wound Healing

11. Vital Proteins for Biomanufacturing Market, by End-Use

  • 11.1. Academic & Research Institutions
  • 11.2. Contract Research Organizations (CROs)
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Vital Proteins for Biomanufacturing Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Vital Proteins for Biomanufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vital Proteins for Biomanufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vital Proteins for Biomanufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Vital Proteins for Biomanufacturing Market

17. China Vital Proteins for Biomanufacturing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2024
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2024
  • 18.3. Product Portfolio Analysis, 2024
  • 18.4. Benchmarking Analysis, 2024
  • 18.5. Danaher Corporation
  • 18.6. Darling Ingredients Inc.
  • 18.7. Gelita AG
  • 18.8. Humabiologics, Inc
  • 18.9. Lonza Group AG
  • 18.10. Merck KGaA
  • 18.11. Nitta Gelatin, Inc.
  • 18.12. Thermo Fisher Scientific Inc.
  • 18.13. Weishardt International

LIST OF FIGURES

  • FIGURE 1. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 13. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN G, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN L, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STREPTAVIDIN/AVIDIN, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FERRITIN & OTHERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN DISULFIDE ISOMERASE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY KINASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIGASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUCLEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYMERASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLLAGENS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBRONECTINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LAMININS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VITRONECTIN, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EGF FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FGF FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY IGF/INSULIN FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS & CHEMOKINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TGF-BETA/BMP FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VEGF/PDGF FAMILY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DEFINED PROTEIN MIXES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT ALBUMIN BLENDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 114. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL-DERIVED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 117. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 120. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 121. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELL SYSTEMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 123. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 126. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PLANT-BASED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 129. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 133. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 136. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AQUACULTURE FEED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 137. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AQUACULTURE FEED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AQUACULTURE FEED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 139. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 140. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 142. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PET FOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 143. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PET FOOD, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PET FOOD, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 146. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 148. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 149. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY HAIR CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 150. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY HAIR CARE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY HAIR CARE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ORAL CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 153. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ORAL CARE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 154. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ORAL CARE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 156. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN CARE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN CARE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 159. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 162. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SCAFFOLD MATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 163. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SCAFFOLD MATERIALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SCAFFOLD MATERIALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 165. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 166. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SURGICAL IMPLANTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 167. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SURGICAL IMPLANTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND DRESSINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 169. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND DRESSINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND DRESSINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 171. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 172. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 174. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 175. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BONE HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 176. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BONE HEALTH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BONE HEALTH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 178. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY JOINT HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 179. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY JOINT HEALTH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY JOINT HEALTH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 182. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN HEALTH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SKIN HEALTH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 184. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SPORTS NUTRITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 185. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SPORTS NUTRITION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SPORTS NUTRITION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 187. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 188. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 190. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 191. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 192. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 193. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 194. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 195. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 197. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 198. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 199. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 200. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 201. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 202. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 205. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 207. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 208. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 210. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 212. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 214. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 215. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 217. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 218. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 219. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 221. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 222. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 223. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 224. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 225. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 226. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 228. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 230. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 231. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 232. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 233. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 234. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 237. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 239. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 240. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 241. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 242. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 243. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 244. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 246. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 248. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 249. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 250. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 251. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 252. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 253. NORTH AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 255. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AFFINITY LIGANDS & BINDING PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 257. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CARRIER PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 258. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHAPERONES & FOLDING AIDS, 2018-2030 (USD MILLION)
  • TABLE 259. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
  • TABLE 260. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXTRACELLULAR MATRIX & COATINGS, 2018-2030 (USD MILLION)
  • TABLE 261. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 262. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SERUM REPLACEMENTS, 2018-2030 (USD MILLION)
  • TABLE 263. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 264. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ANIMAL NUTRITION, 2018-2030 (USD MILLION)
  • TABLE 266. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COSMETICS, 2018-2030 (USD MILLION)
  • TABLE 267. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 268. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 269. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 270. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 271. LATIN AMERICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)

TABLE